Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
US Army
Cipla
Baxter
Colorcon
Teva
Chinese Patent Office
McKinsey
QuintilesIMS

Generated: October 19, 2018

DrugPatentWatch Database Preview

ALTABAX Drug Profile

« Back to Dashboard

Which patents cover Altabax, and what generic alternatives are available?

Altabax is a drug marketed by Aqua Pharms Llc and is included in one NDA. There are three patents protecting this drug.

The generic ingredient in ALTABAX is retapamulin. Two suppliers are listed for this compound. Additional details are available on the retapamulin profile page.

Summary for ALTABAX
Drug patent expirations by year for ALTABAX
Generic Entry Opportunity Date for ALTABAX
Generic Entry Date for ALTABAX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
OINTMENT;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ALTABAX
Synonyms for ALTABAX
(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxotricyclo[5.4.3.0;{1,8}]tetradecan-6-yl 2-{[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl}acetate
(3aS,4R,5S,6S,8R,9R,9aR,10R)-2-(exo-8-Methyl-8-azabicyclo[3.2.1]octan-3-ylsulfanyl)acetic acid 5-hydroxy-4,6,9,10-tetraMethyl-1-oxo-6-vinylperhydro-3a,9-propanocyclopentacycloocten-8-yl ester (RETAPAMULIN)
(3as,4r,5s,6s,8r,9r,9ar,10r)-5-Hydroxy-4,6,9,10-Tetramethyl-1-Oxo-6-Vinyldecahydro-3a,9-Propanocyclopenta[8]annulen-8-Yl {[(3-Exo)-8-Methyl-8-Azabicyclo[3.2.1]oct-3-Yl]thio}acetate
224452-66-8
345632-67-9
452R668
4MG6O8991R
AB01566905_01
AK110479
AKOS016008865
AKOS030485971
Altabax (Glaxo)
Altargo
AN-607
AS-11455
BC677692
C30H47NO4S
CR0022
CS-0618
DB01256
HY-17010
MFCD11045316
MolPort-006-167-754
MolPort-023-220-081
MP-0763
Retapamulin
Retapamulin [USAN:INN:BAN]
retpamulin
RL02708
s4056
SB 275833
SB-275833
SB275833
SCHEMBL365459
ST24025747
UNII-4MG6O8991R
ZINC100013500
ZINC103660515
ZINC3931840

US Patents and Regulatory Information for ALTABAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aqua Pharms Llc ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Aqua Pharms Llc ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Aqua Pharms Llc ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for ALTABAX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C042/2007 Ireland ➤ Sign Up SPC042/2007: 20080415, EXPIRES: 20220523
C/GB07/061 United Kingdom ➤ Sign Up PRODUCT NAME: RETAPAMULIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/390/001 20070524; UK EU/1/07/390/002 20070524; UK EU/1/07/390/003 20070524; UK EU/1/07/390/004 20070524
C0057 France ➤ Sign Up PRODUCT NAME: RETAPAMULIN; REGISTRATION NO/DATE IN FRANCE: EU/1/07/390/001 DU 20070524; REGISTRATION NO/DATE AT EEC: EU/1/07/390/001 DU 20070524
372 Luxembourg ➤ Sign Up 91372, EXPIRES: 20220524
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
US Army
Cipla
Baxter
Colorcon
Teva
Chinese Patent Office
McKinsey
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.